Immunotherapy-combined chemotherapy as first-line treatment for stage IIIB/IV large cell neuroendocrine lung carcinoma.

Li Z, Xu Z, Wang L, Mao X, Huo T, Jin C

Open source

DOI
10.62347/ptpr2634
Published
2026
Container
American journal of translational research
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.62347/ptpr2634,
  title = {Immunotherapy-combined chemotherapy as first-line treatment for stage IIIB/IV large cell neuroendocrine lung carcinoma.},
  author = {Li Z and Xu Z and Wang L and Mao X and Huo T and Jin C},
  year = {2026},
  journal = {American journal of translational research},
  doi = {10.62347/ptpr2634},
  url = {https://doi.org/10.62347/ptpr2634}
}

RIS

TY  - JOUR
TI  - Immunotherapy-combined chemotherapy as first-line treatment for stage IIIB/IV large cell neuroendocrine lung carcinoma.
AU  - Li Z
AU  - Xu Z
AU  - Wang L
AU  - Mao X
AU  - Huo T
AU  - Jin C
PY  - 2026
JO  - American journal of translational research
DO  - 10.62347/ptpr2634
UR  - https://doi.org/10.62347/ptpr2634
ER  - 

APA

Z, L., Z, X., L, W., X, M., T, H., & C, J. (2026). Immunotherapy-combined chemotherapy as first-line treatment for stage IIIB/IV large cell neuroendocrine lung carcinoma.. American journal of translational research. https://doi.org/10.62347/ptpr2634

Source records